Source - GNW
 

ORION CORPORATION      STOCK EXCHANGE RELEASE 5 OCTOBER 2016 at 9.00 a.m. EEST              

100,000 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 100,000 A shares have been converted into 100,000 B shares. The conversion has been entered into the Trade Register on 5 October 2016.

The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 38,481,154 A shares and 102,776,674 B shares.

  
Orion Corporation

Olli Huotari
SVP, Corporate Functions
  Jari Karlson
CFO
 

                                                                       
                                                                       
Contact person:
Tuukka Hirvonen, Manager, Investor Relations & Financial Communications, tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2015 amounted to EUR 1,016 million and the company had about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire